Pharmacology

Lindsay Hallman, CVT, CCMT, VTS (Oncology), and Katelyn McDonald, CVT, VTS (Oncology), discuss clinical administration of oncology therapy, in a dvm360 interview.

The single-injection monoclonal antibody (Lenivia) from Zoetis reduces OA pain in dogs for 3 months.

Lindsay Hallman, CVT, CCMT, VTS (Oncology), and Katelyn McDonald, CVT, VTS (Oncology), discuss what oncology patients may experience in a dvm360 interview.

Boehringer Ingelheim earned positive opinions for 2 immunization therapies in the pipeline.

OS Therapeutics' veterinary division is developing OST-HER2 for canine osteosarcoma treatment.

Gallant is developing FDA-regulated, off-the-shelf mesenchymal stromal cell therapies to rapidly modulate inflammation, support tissue repair, and make stem cell treatment broadly available to cats and dogs.

The study results place the American foulbrood prevention therapy closer to full USDA licensure.

This completion is a crucial requirement in the approval process for a drug.

Zoetis’ Vanguard Recombishield is a nonadjuvanted, recombinant injectable therapy.

Solovecin by Dechra is a generic antibiotic for the treatment of skin infections in dogs and cats.

Felixvet has announced the approval for a bioequivalent product to Simplicef (Zoetis).

Akston Biosciences Corporation partnered with Purdue University to develop a drug targeting PD-L1 in dogs with solid tumors.

Zoetis' relfovetmab product is a long-acting anti–nerve growth factor monoclonal therapy for cats.

The 2 drugs from Elanco now offer protection from emerging tick species and aid in the prevention of Lyme disease in canines.

Zoetis' drug was recently approved in Canada and recommended in Europe.

A doctorate student at UC Davis is receiving up to $10,000 in funding to support their research efforts.

A West Virginia veterinarian faces nearly $1 million in penalties for failing to account for controlled substances and allegedly falsifying records.

Updates on a new vaccine to help protect koalas from chlamydia, and a virtual learning environment providing on-demand professional development for species-specific and mixed-practice veterinarians.

The long-lasting injection was first cleared in Australia and New Zealand in 2023.

Zoetis' Dectomax-CA1 is the first drug to receive conditional approval in the US for addressing this type of parasitic infestation.

The revision removes language about fatal vaccine-induced disease from the skin allergy drug's label.

The agency found that Gallant’s data provides reasonable expectation of effectiveness.

Felixvet's Clindamycin Hydrochloride Tablets gain FDA approval, offering a new oral antibiotic option for treating various canine infections.

Generic furosemide is used to help manage heart failure.